Particle.news

Download on the App Store

New Study Reveals Abortion Pill Complication Rate 22 Times Higher Than FDA Estimate

Analysis of over 865,000 mifepristone prescriptions shows nearly 11% of users experience serious adverse events, prompting calls for stricter FDA oversight.

Overview

  • A large-scale study by the Ethics and Public Policy Center analyzed insurance claims data from 2017 to 2023, covering over 865,000 mifepristone prescriptions.
  • The study found a 10.9% rate of serious complications, including hemorrhage, infection, sepsis, and follow-up surgeries, significantly higher than the FDA's reported rate of less than 0.5%.
  • Researchers argue that the FDA's data, based on clinical trials from 30,966 participants, does not reflect real-world conditions and excludes non-fatal complications.
  • The study urges the FDA to reinstate stricter safety protocols, including in-person visits, physician-only prescriptions, ultrasounds, and mandatory complication reporting.
  • FDA Commissioner Marty Makary has stated there are no immediate plans to alter current regulations but remains open to action based on data-driven evidence.